Hyperfine Inc logo

Hyperfine Inc(HYPR)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.63
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for HYPR

11/13/2026: HYPR (1-star) is currently NOT-A-BUY. Pass it for now.

Hyperfine Inc is a commercial-stage medical technology company that provides the Swoop Portable MR Imaging system for bedside brain scans. The company's primary strength lies in its pioneering ultra-low-field portable MRI technology, which enables neuroimaging inside intensive care units and resource-constrained environments. Its main growth opportunity centers on expanding hospital adoption and securing broader international regulatory approvals. However, investors face execution risks, ongoing operating losses, and competition from legacy medical device giants. The stock is best suited for growth-oriented investors willing to monitor hospital adoption trends and cash runway management.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitHyperfine offers speculative long-term top-line expansion potential rooted in its novel portable MRI technology.
Momentum investorMixed fitMomentum fit depends heavily on periodic clinical catalysts, earnings updates, or broader biotech/medtech rallies.
Value investorWeak fitThe company is currently unprofitable and trades on future commercial promise rather than near-term earnings or asset backing.
Dividend investorWeak fitHyperfine does not pay dividends and retains all capital to fund commercialization and growth.
Low-risk investorWeak fitHigh volatility, execution risk, and cash burn make this stock unsuitable for conservative or risk-averse investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSmall-cap medtech stocks frequently experience sharp price swings based on market sentiment and funding updates.
Valuation riskMedium / highValuation relies heavily on long-term adoption assumptions rather than established near-term cash flows.
Competition risk (large medical device incumbents)MediumWell-capitalized legacy medical equipment giants could eventually target the portable MRI niche.
Business qualityMediumProprietary FDA-cleared technology provides a defensible moat, though commercial scale is still developing.
Dividend incomeLow / noneNo cash returns are distributed to shareholders via dividends.
Execution riskHighSuccess depends entirely on hospital adoption rates, physician acceptance, and expanding reimbursement coverage.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 66.74M USD
Price to earnings Ratio -
1Y Target Price 2.02
Price to earnings Ratio -
1Y Target Price 2.02
Volume (30-day avg) 998.5K shares
Beta 1.5
52 Weeks Range 0.61 - 1.94
Updated Date 11/15/2026
52 Weeks Range 0.61 - 1.94
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.29

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 42.82%
Avg. Invested days 34
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
HYPR receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
HYPR has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, solid earnings growth (+12.6%) is partially offset by weak cash generation (FCF margin -214.8%), moderate revenue growth (+5.2%), weak profitability (net margin -262.3%).

Financial Health Rating

★★★★★
HYPR's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 70.9%). Operating efficiency is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is HYPR's strongest growth driver at +25.6% FY2025 versus FY2024 (solid, 4 stars). Revenue growth (+5.2%, moderate) and earnings growth (+12.6%, solid) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 22.1% (moderate) and 95.1% of outstanding shares are publicly tradable (strong). Insider ownership of 4.48% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 4.40%
Vanguard Capital Management, LLC 3.18%
Geode Capital Management, LLC 1.85%
Fosun International Ltd 1.64%
Catalio Capital Management, LP 1.24%

Unit Economics (Per $1K Revenue)

★★★★★
HYPR generates approximately $498 of gross profit, $-2,734 of operating income, and $-2,148 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
HYPR has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Swoop System Product SalesRevenue generated from the direct sale or placement of Swoop portable MRI hardware units to hospitals and clinics.The company sells specialized hardware devices designed to fit inside standard hospital elevators and rooms.
Services and SoftwareRecurring revenue derived from maintenance, software licenses, AI processing features, and customer support contracts.Provides a steady stream of recurring service and software upgrade revenue once equipment is installed.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 42.08M
Price to Sales(TTM) 3.5
Enterprise Value 42.08M
Price to Sales(TTM) 3.5
Enterprise Value to Revenue 2.21
Enterprise Value to EBITDA -0.72
Shares Outstanding 90.99M
Shares Floating 86.57M
Shares Outstanding 90.99M
Shares Floating 86.57M
Percent Insiders 4.48
Percent Institutions 22.09

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.